Molecular sources of residual cardiovascular risk, clinical signals, and innovative solutions: relationship with subclinical disease, undertreatment, and poor adherence: implications of new evidence upon optimizing cardiovascular patient outcomes.
about
Triglyceride-rich lipoproteins as a causal factor for cardiovascular diseaseNiacin in the Treatment of Hyperlipidemias in Light of New Clinical Trials: Has Niacin Lost its Place?Residual Cardiovascular Risk in Chronic Kidney Disease: Role of High-density LipoproteinGammadelta (γδ) T lymphocytes do not impact the development of early atherosclerosis.Anti-atherosclerotic effect of traditional fermented cheese whey in atherosclerotic rabbits and identification of probiotics.Serum uric acid as a prognostic marker in the setting of advanced vascular disease: a prospective study in the elderly.Nature and nurture in atherosclerosis: The roles of acylcarnitine and cell membrane-fatty acid intermediates.Residual cardiovascular risk in patients who received lipid-lowering treatment in a real-life setting: retrospective studyImpact of variants in CETP and apo AI genes on serum HDL cholesterol levels in men and women from the Polish populationPoLA/CFPiP/PCS Guidelines for the Management of Dyslipidaemias for Family Physicians 2016.Looking into the crystal ball-upcoming drugs for dyslipidemia.Revising the high-density lipoprotein targeting strategies - insights from human and preclinical studies.Current Treatment of Dyslipidemia: Evolving Roles of Non-Statin and Newer Drugs.Virtual exploration of early stage atherosclerosis.Effect of valsartan on ACAT-1 and PPAR-γ expression in intima with carotid artery endothelial balloon injury in rabbit.n-3 Polyunsaturated Fatty Acids and Cardiovascular Disease: Principles, Practices, Pitfalls, and Promises; A Contemporary Review.Cultural primer for cardiometabolic health: health disparities, structural factors, community, pathways to improvement, and clinical applications.Fibrates in the management of atherogenic dyslipidemia.Do HDL and LDL subfractions play a role in atherosclerosis in end-stage renal disease (ESRD) patients?A Meta-Prediction of Polymorphisms and Air Pollution Increased the Risk of Ischemic Heart Diseases Worldwide
P2860
Q26745946-B3463912-26D7-4931-A24E-B9F48E90898EQ26799534-1D46389D-A65F-4B0A-8161-CF1D63FBECD4Q28083619-DF3A60CD-A133-466B-894E-6A31B5CCA270Q35748386-ABE850E1-224B-4E0C-8314-F57493F0ADF7Q36110882-07DD330A-6CD4-4913-B303-08FD4E129571Q36162192-0A5A2E0E-835A-4279-B910-0CDD96C91F48Q36418591-EC735D3C-B411-48E1-A76A-70D0017701EFQ37381149-2C63E1B5-8FB1-4444-90EA-D5DF07A15740Q37412661-1FB85779-EA4A-4C8C-A9B2-05DA5437E57EQ37549374-5E8E11EC-7316-4820-AFC8-5D0FF439D99FQ38235611-26E02F33-3531-4EBF-9543-823E8E02556BQ38239205-73C235AD-0C41-4C23-976E-7B3EBC3BF6A1Q38546242-70DE5C22-61A3-49E4-A732-38628C1461BFQ39437318-0E3CDB45-5297-4F03-98CD-C860AFA2B588Q41643978-9BE5CD36-8A20-4858-9E09-470CA62958C5Q47396742-03CDAE63-2FDC-4342-9DF2-8605D0645D82Q47567689-D1B4D783-7937-44BF-937B-A86D4D4367D2Q49571281-AF9964AD-D903-48FA-9BAB-2487BE4B9031Q51273079-FA041C2E-C740-4543-BC6B-481CBB0DC245Q57176599-C296084E-6B5A-4A4B-8AE9-0CE6D57B1920
P2860
Molecular sources of residual cardiovascular risk, clinical signals, and innovative solutions: relationship with subclinical disease, undertreatment, and poor adherence: implications of new evidence upon optimizing cardiovascular patient outcomes.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 21 October 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Molecular sources of residual ...... rdiovascular patient outcomes.
@en
Molecular sources of residual ...... rdiovascular patient outcomes.
@nl
type
label
Molecular sources of residual ...... rdiovascular patient outcomes.
@en
Molecular sources of residual ...... rdiovascular patient outcomes.
@nl
prefLabel
Molecular sources of residual ...... rdiovascular patient outcomes.
@en
Molecular sources of residual ...... rdiovascular patient outcomes.
@nl
P2860
P921
P356
P1476
Molecular sources of residual ...... rdiovascular patient outcomes.
@en
P2093
Richard Kones
P2860
P304
P356
10.2147/VHRM.S37119
P407
P5008
P577
2013-10-21T00:00:00Z